CBP/p300-IN-19

Cat. No.:	HY-146277
CAS No.:	2592638-13-4
Molecular Formula:	$C_{30}H_{27}N_3O_3$
Molecular Weight:	477.55
Target:	Histone Acetyltransferase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC_{50}s of 1.4, 2.2, >100, >100 μM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity[1].

IC_{50} & Target	Myst3	p300-HAT	CBP-HAT	PCAF
	>100 μM (IC_{50})	1.4 μM (IC_{50})	2.2 μM (IC_{50})	>100 μM (IC_{50})

In Vitro

CBP/p300-IN-19 (compound 29) shows antiproliferative activity with EC_{50}s of 5.3, 8.5, 6.2, 4.4, 1.2, 4.3, 3.6, 8.7, 6.4 μM for MCF-7, MDA-MB231, LNCaP, PC-3, PANC-1, MDA-PANC-28, Molm-13, MV4;11, RPMI-8226 cells, respectively[1].

CBP/p300-IN-19 (0, 5, 10 μM; 12 h) dose-dependently inhibits the acetylation of H3K18, H3K9 and K27[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	Kasumi-1 leukemia cells
Concentration:	0, 5, 10 μM
Incubation Time:	12 h
Result:	Dose-dependently inhibited the acetylation of H3K18, H3K9 and K27.

REFERENCES

[1]. Nie S, et al. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP. Eur J Med Chem. 2022 Jul 5;237:114407.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA